Pfizer and BioNTech announced Tuesday they are requesting emergency use authorization for their two-dose COVID-19 vaccine for children 6 months through 4 years of age.

Food and Drug Administration authorization could come as soon as late February, making the Pfizer-BioNTech vaccine the first authorized COVID-19 vaccine for that age group, the New York Times reported. But data released in December indicate that it might not produce an adequate immune response for most of the age group.